Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 901–1,000 of 1,000
Ravanbod, R., Torkaman, G., Mofid, M., & Mohammadali, F. (2015) · Haemophilia · doi:10.1111/hae.12659 · Cited by 13
Bleeding Disorders in Orthopedic Surgery
Mansour, J., Graf, K. W., & Lafferty, P. M. (2012) · Orthopedics · doi:10.3928/01477447-20121120-09 · Cited by 13
Prophylaxis use among males with haemophilia B in the United States
Ullman, M. M., Zhang, Q. C., Grosse, S. D., Recht, M., & Soucie, J. M. (2017) · Haemophilia · doi:10.1111/hae.13317 · Cited by 13
“7,8 Both studies demonstrated the ability of preventative therapy to reduce joint damage compared to factor administered after bleeding.”
Self-citationThe role of prophylaxis in the management of von Willebrand disease: today and tomorrow
Abshire, T. C. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70153-7 · Cited by 13
Self-citationCollision Sports and Risk of Bleeding in Children With Hemophilia
Manco‐Johnson, M. J. (2012) · JAMA · doi:10.1001/jama.2012.13303 · Cited by 14
Self-citationCarlsson, K. S., Winding, B., Astermark, J., Baghaei, F., Brodin, E., Funding, E., Holmström, M., Österholm, K., Bergenstråle, S., & Lethagen, S. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.100061 · Cited by 14
“[25] Prevention of bleeds, especially in joints, has been a longstanding objective in hemophilia care, [2,26,27] and the favorable outcome of regular prophylactic treatment for severe hemophilia has been established in observational [28,29] and trial data [30] for decades.”
Activation of the Acute-Phase Response in Hemophilia
Knowles, L. M., Wolter, C., Menger, M. D., Laschke, M. W., Beyer, L., Grün, U. W., Eichler, H., & Pilch, J. (2023) · Thrombosis and Haemostasis · doi:10.1055/a-2071-0477 · Cited by 14
“8,10,11 14 As such, it has been shown that anti-in fl ammatory treatment with a function blocking antibody against IL-6R α in conjunction with clotting factor concentrates can mitigate hemophilic arthropathyafterjoint bleedsintransgenichemophiliamice.”
Hermans, C. R. J. R., & Pierce, G. F. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.100173 · Cited by 12
“arthropathy, a sign of uncontrolled subclinical bleeding due to inadequately low FVIII trough levels [17,18].”
BackgroundCastaman, G., Coppens, M., & Pipe, S. W. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2276206 · Cited by 12
Ozelo, M. C., Hermans, C. R. J. R., Carcao, M. D., Guillet, B., Gu, J., Guerra, R., Tang, L., & Khair, K. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207231218624 · Cited by 12
Haemophilic arthropathy: Diagnosis, management, and aging patient considerations
Bakeer, N., Saied, W., Gavrilovski, A., & Bailey, C. (2024) · Haemophilia · doi:10.1111/hae.15004 · Cited by 12
“3,5 MRIdataindicatethatjointdamagecanstillbeidentifiedinabout20% ofclinicallyasymptomaticpatientsevenwhilereceivingprophylaxis, 4,5 and maintaining factor levels over a certain threshold and essentially converting severe haemophilia patients to mild or moderate ones does not fully prevent…”
BackgroundCoppola, A., Zani, M., Quintavalle, G., Focosi, D., & Franchini, M. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1796629 · Cited by 14
“29 The long-term ef fi cacy of prophylaxis in preventing bleeds and arthropathy in children with hemophilia was con fi rmed by another RCT with a 10-year follow-up.”
Duncan, N., Roberson, C., Lail, A. E., Donfield, S. M., & Shapiro, A. D. (2014) · Haemophilia · doi:10.1111/hae.12370 · Cited by 12
Self-citationMolecular approaches for improved clotting factors for hemophilia
Kaufman, R. J., & Powell, J. S. (2013) · Hematology · doi:10.1182/asheducation-2013.1.30 · Cited by 12
Registry‐based outcome assessment in haemophilia: a scoping study to explore the available evidence
Osooli, M., & Berntorp, E. E. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12434 · Cited by 12
Horava, S. D., Moy, K. J., & Peppas, N. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.056 · Cited by 12
Miesbach, W., & Sawyer, E. K. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.253 · Cited by 12
“44–46 In this respect, gene transfer may improve longer-term clinical outcomes by offering the possibility of averting these microbleeds (and thus improving or preventing joint disease) with higher constant FIX rather than peaks and troughs.”
Fukutake, K., Taki, M., Matsushita, T., Nogami, K., Shima, M., Yoshioka, A., Takamatsu, J., Uchikawa, H., Takagi, H., Arai, M., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-018-02574-x · Cited by 12
Vøls, K. K., Kjelgaard-Hansen, M. J., Ley, C. D., Hansen, A. K., & Petersen, M. (2019) · Haemophilia · doi:10.1111/hae.13672 · Cited by 12
Redefining prophylaxis in the modern era
Mahlangu, J. N., Blanchette, V. S., & Klamroth, R. (2020) · Haemophilia · doi:10.1111/hae.14035 · Cited by 12
Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A
Yamaki, Y., Fukushima, T., Yoshida, N., Nishimura, K., Fukuda, A., Hisatake, K., Aso, M., Sakasai, T., Kijima-Tanaka, J., Miwa, Y., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03059-6 · Cited by 13
“Initiation of prophylaxis with coagulation factor preparations from early childhood to prevent hemophilic arthropathy is now a widely accepted practice [8].”
BackgroundProphylaxis in hemophilia: how much is enough?
Kempton, C. L. (2021) · Blood · doi:10.1182/blood.2020009603 · Cited by 12
Bukkems, L. H., Valke, L. L. F. G., Barteling, W., Gorkom, B. A. P. L., Blijlevens, N. M. A., Cnossen, M. H., van Heerde, W. L., Schols, S. E. M., & Mathôt, R. A. A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15185 · Cited by 12
“During recent decades, treatment has altered from ondemand treatment to prophylactic therapy for patients with severe haemophilia.(2) However, a large inter-individual variability in the”
BackgroundManaging Severe Hemophilia A in Children: Pharmacotherapeutic Options
Regling, K., Callaghan, M. U., & Sidonio, R. F. (2022) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s293246 · Cited by 12
“Prophylaxis with FVIII concentrates was, until recently, the gold standard of treatment for severe HA and has significantly improved the overall bone and joint health in these patients.(2,3) In addition, the use of prophylaxis also leads to a marked”
BackgroundLong-term impact of primary prophylaxis on joint status in patients with severe hemophilia A
Meijon-Ortigueira, M. D. M., Román, M. T. Á., Rodríguez, H. D. L. C., Coll, N. B., & Jiménez‐Yuste, V. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2022.100005 · Cited by 12
“[36] compared the occurrence of joint involvement in both groups, documenting the development of damage by MRI after a mean participation period of 49 months in 45% of patients receiving episodic treatment versus 7% of patients on prophylaxis.”
BackgroundProfile of efraloctocog alfa and its potential in the treatment of hemophilia A
Camire, R. M., & George, L. A. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s54632 · Cited by 14
Buyue, Y., Liu, T., Kulman, J. D., Toby, G. G., Kamphaus, G. D., Patarroyo-White, S. L., Lü, Q., Reidy, T. J., Mei, B., Jiang, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113600 · Cited by 13
“Hemophilia A is an X-linked bleeding disorder caused by deficiency of factor VIII (FVIII) activity [1, 2].”
BackgroundRolstad, E. B. (2014) · American Journal of Men s Health · doi:10.1177/1557988314551360 · Cited by 12
Advances in Hemophilia: Experimental Aspects and Therapy
Rodriguez, N. I., & Hoots, W. K. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.003 · Cited by 12
“Manco-Johnson and colleagues [4] recently published the results of the first prospective, randomized, controlled clinical trial in the United States evaluating the progression of arthropathy in children who have hemophilia treated with prophylaxis versus on-demand therapy.”
Self-citationCost‐effectiveness analysis of different imaging strategies for diagnosis of haemophilic arthropathy
KHAN, U., Bogue, C., Ungar, W. J., Hilliard, P., Carcao, M. D., Moineddin, R., & Doria, A. S. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02125.x · Cited by 12
Orthopaedic procedures in haemophilia
Rizzo, A. R. (2017) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2017.14.1.197 · Cited by 12
Chai‐Adisaksopha, C., Skinner, M. W., Curtis, R., Frick, N., Nichol, M. B., Noone, D., O’Mahony, B., Page, D., Stonebraker, J. S., Thabane, L., et al. (2019) · Haemophilia · doi:10.1111/hae.13703 · Cited by 12
Investigational drugs to treat hemophilia
Franchini, M., Marano, G., Pati, I., Veropalumbo, E., Vaglio, S., Pupella, S., Masiello, F., Cruciani, M., Mengoli, C., & Liumbruno, G. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1722999 · Cited by 12
“hemophilia care, reducing the risk of hemophilic arthropathy and improving the quality of life and survival of patients [6,7].”
BackgroundMeeks, S. L., & Lacroix‐Desmazes, S. (2020) · Haemophilia · doi:10.1111/hae.14123 · Cited by 12
Cuesta‐Barriuso, R., Pérez‐Llanes, R., Donoso‐Úbeda, E., Pina, J. A. L., & Meroño‐Gallut, J. (2021) · Medicine · doi:10.1097/md.0000000000026025 · Cited by 13
Xue, F., Zhao, X., Sun, J., Zeng, X., Yang, F., Xu, M., Yu, Z., Gu, W., Feng, Y., Li, W., et al. (2021) · Haemophilia · doi:10.1111/hae.14350 · Cited by 12
Experiences in the prevention of arthropathy in haemophila patients with inhibitors
Jiménez‐Yuste, V., Rodriguez-Merchan, E. C., Álvarez, M. T., QUINTANA, M., Martín‐Salces, M., & Hernandez-Navarro, F. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01887.x · Cited by 12
Amby, L. K., Seremetis, S. V., Obergfell, A., & Bjerre, J. (2009) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32832c8803 · Cited by 12
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex
Marlu, R., & Polack, B. (2012) · Haematologica · doi:10.3324/haematol.2011.055699 · Cited by 12
“In recent years, the treatment of patients with severe hemophilia has improved considerably because of the greater availability of concentrates, allowing widespread adoption of prophylaxis to prevent bleeding episodes.(2) However, for hemophilia A in particular, the development of antibodies inhibiting the activity of…”
BackgroundManaging Haemophilia for Life: 5th Haemophilia Global Summit
Hermans, C. R. J. R., Dolan, G., Jennings, I., Windyga, J., Lobet, S., Rodriguez-Merchan, E. C., Minno, M. N. D. D., Jiménez‐Yuste, V., & O’Mahony, B. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12617 · Cited by 12
“Standard prophylaxis is currently prescribed on the basis of weight; however, evidence has shown that this is not directly proportional to half-life, and therefore, substantial interpatient variation in the resulting trough level is likely to be observed (4, 8, 9).”
BackgroundInfluentialInvestigational drugs for coagulation disorders
Mannucci, P. M., & Mancuso, M. E. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.798302 · Cited by 12
“In the frame of this favorable scenario, the optimal form of replacement therapy delivery in PWH is regular prophylaxis, which was shown to be superior to episodic treatment by two randomized clinical trials [5,6].”
BackgroundOctocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®)
Dhillon, S. (2012) · Drugs · doi:10.2165/11207480-000000000-00000 · Cited by 12
“006) more patients receiving prophylaxis had normal indexjoint structure than those receiving on-demand therapy (65 children aged <30months were enrolled and received Kogenate or Kogenate FS; assessments were conducted at the age of 6 years).([44]) Prophylaxis may also be beneficial in adults.”
BackgroundHemophilia in Sports: A Case Report and Prophylactic Protocol
Maffet, M. W., & Roton, J. (2016) · Journal of Athletic Training · doi:10.4085/1062-6050-51.11.14 · Cited by 12
Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care
Dushimova, Z., Pashimov, M., Kaibullayeva, J. A., Danyarova, L., Kultanova, E., Abdilova, G., & Mustapayeva, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618464 · Cited by 15
“The advent of recombinant FVIII and later recombinant FIX enhanced treatment safety by decreasing dependence on plasma-derived products (28, 29).”
Ljung, R. C. R., de Kovel, M., van den Berg, H. M., & the PedNet study group (2022) · Haemophilia · doi:10.1111/hae.14729 · Cited by 11
Hermans, C. R. J. R., Skinner, M. W., Gentile, B., Lim, E., Minhas, M., Moreno, K., Tzeng, E., & Buckner, T. W. (2024) · Haemophilia · doi:10.1111/hae.15134 · Cited by 11
Amano, K., Fujii, T., Sawada, A., Nagao, A., Nagae, C., Nojima, M., Suzuki, N., Kawano, M., Shimura, T., Sugao, Y., et al. (2025) · Haemophilia · doi:10.1111/hae.70070 · Cited by 11
Pöllmann, H., Klamroth, R., Vidovic, N., Kriukov, A. Y., Epstein, J., Abraham, I., Spotts, G. E., & Oldenburg, J. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1678-4 · Cited by 11
“primary prophylaxis over on-demand therapy for young boys [18].”
BackgroundResultInfluentialPreventing bleeds by treatment: new era for haemophilia changing the paradigm
van den Berg, H. M. (2016) · Haemophilia · doi:10.1111/hae.12993 · Cited by 12
Hemophilia and von Willebrand disease
Bleasel, J. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00194-7 · Cited by 11
Clinical and ultrasound evaluation of patients with haemophilia on prophylaxis
Daffunchio, C., Galatro, G. A., Rossi, M., Landro, M. E., Andreu, M. F., Neme, D., & Caviglia, H. A. (2021) · Haemophilia · doi:10.1111/hae.14312 · Cited by 11
Cortesi, P. A., Rocino, A., Preti, D., Fragomeno, A., Cucuzza, F., Ceresi, N., Santoro, C., Ferretti, A., Fornari, A., Antonazzo, I. C., et al. (2022) · Haemophilia · doi:10.1111/hae.14504 · Cited by 11
Special lectures in haemophilia management
Bátorová, A., High, K. A., & Gringeri, A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02289.x · Cited by 13
The role of prophylaxis in bleeding disorders
Berntorp, E. E., de Moerloose, P., & Ljung, R. C. R. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02319.x · Cited by 11
The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation
Plesner, B., Westh, P., Hvidt, S., & Nielsen, A. D. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.02.028 · Cited by 11
Haxaire, C., & Blobel, C. (2014) · Haemophilia · doi:10.1111/hae.12416 · Cited by 11
Cuesta‐Barriuso, R., Torres‐Ortuño, A., López‐García, M., & Nieto‐Munuera, J. (2014) · Haemophilia · doi:10.1111/hae.12447 · Cited by 11
Windyga, J., Chojnowski, K., Klukowska, A., Łętowska, M., Mital, A., Musiał, J., Peregud-Pogorzelski, J. W., Podolak‐Dawidziak, M., Treliński, J., Undas, A., et al. (2016) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2016.04.009 · Cited by 19
“W dwóch randomizowanych badaniach klinicznych wykazano, że w porównaniu z leczeniem według zasady „na żądanie”, długoterminowa profilaktyka krwawień u dzieci z ciężką hemofilią A z zastosowaniem rFVIII prowadzi do zmniejszenia częstości krwawień, ograniczenia rozwoju artropatii oraz podniesienia jakości życia zależnej…”
InfluentialLi, Z., Wu, J. H., Zhao, Y., Liu, R., Li, K., Zhou, Y., Wu, R., Yang, R., Zhang, X., Lian, S., et al. (2017) · Haemophilia · doi:10.1111/hae.13372 · Cited by 11
Neufeld, E. J., Sidonio, R. F., O’Day, K., Runken, M. C., Meyer, K. L., & Spears, J. B. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1468335 · Cited by 12
Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors
Teitel, J. M. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.07.011 · Cited by 11
Cerebral microbleeds: hearing through the silence—a narrative review
Humphries, T. J., & Mathew, P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1521787 · Cited by 12
“Manco-Johnson et al.(3); Seuser(4); Staritz et al.”
Self-citationDelavenne, X., Dargaud, Y. G., Ollier, É., & Négrier, C. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13858 · Cited by 10
Oldenburg, J., Hay, C. R. M., Jiménez‐Yuste, V., Peyvandi, F., Schved, J., Szamosi, J., Winding, B., & Lethagen, S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028012 · Cited by 11
Low Dose Prophylaxis in Hemophilia Care
Sidharthan, N., & Sudevan, R. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01147-0 · Cited by 11
How Do I Counsel Parents of a Newly Diagnosed Boy with Haemophilia A?
Kurnik, K., Bidlingmaier, C., & Olivieri, M. (2020) · Hämostaseologie · doi:10.1055/s-0039-3402805 · Cited by 11
Current and Future Options of Haemophilia A Treatments
Miesbach, W., & Eladly, F. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1908993 · Cited by 12
Costs and management of patients with hemophilia A in France: the Hemraude study
Laurendeau, C., Goudemand, J., Trossaërt, M., Polack, B., Varin, R., Godard, C., Hadim, F., & Detournay, B. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01339-4 · Cited by 11
Ettingshausen, C. E., & Sidonio, R. F. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211032452 · Cited by 12
Stimec, J., Dover, S., Pullenayegum, E., Blanchette, V. S., Doria, A. S., Feldman, B. M., Carcao, M. D., Rivard, G., Israels, S. J., Chan, A. K. C., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12565 · Cited by 11
van Leeuwen, F. H. P., Timmer, M. A., de Jong, P. A., Fischer, K., & Foppen, W. (2023) · Haemophilia · doi:10.1111/hae.14737 · Cited by 12
Preoperative Evaluation and Preparation of Patients for Orthopedic Surgery
Abel, R. B., & Rosenblatt, M. A. (2014) · Anesthesiology Clinics · doi:10.1016/j.anclin.2014.08.007 · Cited by 11
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
Puetz, J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6628 · Cited by 11
Haemophilic magnetic resonance imaging score in healthy controls playing sports
Foppen, W., Sluiter, D., Witkamp, T. D., Mali, W. P. T. M., & Fischer, K. (2013) · Haemophilia · doi:10.1111/hae.12191 · Cited by 11
Saba, & Tran (2012) · Journal of Blood Medicine · doi:10.2147/jbm.s30479 · Cited by 13
“It has been demonstrated that long-term outcomes are best achieved when prophylactic treatment is started before the age of 3 years.(20,46,47) Fewer adults and adolescents than children receive prophylactic treatment, and currently there is no consensus as to when, or whether, prophylactic treatment could be discontin…”
Rea, C. J., Foley, J. H., Bevan, D. H., & Sørensen, B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1921-z · Cited by 11
von Willebrand disease in the 21st century: current approaches and new challenges
Mannucci, P. M., Federici, A. B., James, A., & Kessler, C. M. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2008.01932.x · Cited by 11
Hereditary Clotting Factor Deficiencies (Bleeding Disorders)
Scott, J. P., & Montgomery, R. R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00470-x · Cited by 11
Comparison of joint status in children with haemophilia A using ultrasound and physical examination
Aspdahl, M., Viljakainen, H. T., Petrini, P., & Ranta, S. (2018) · European Journal of Physiotherapy · doi:10.1080/21679169.2018.1438511 · Cited by 11
Rode, F., Almholt, K., Petersen, M., Kreilgaard, M., Kjalke, M., Karpf, D. M., Groth, A. V., Johansen, P. B., Larsen, L. F., Loftager, M., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14013 · Cited by 12
Blatný, J., Kardos, M., Miljić, P., Bilić, E., Benedik‐Dolničar, M., Kotnik, B. F., Konstantinov, D., Kovalova, Z., & Ovesná, P. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.004 · Cited by 13
Pipe, S. W. (2009) · Biologics · doi:10.2147/btt.s3191 · Cited by 11
Hemophilias and Other Disorders of Hemostasis
Shavit, J. A., & Ginsburg, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05545-8 · Cited by 11
Hemophilia severity score system: validation from an Italian Regional Hemophilia Reference Center
Tagliaferri, A., Perna, C. D., Franchini, M., Rivolta, G. F., & Pattacini, C. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03288.x · Cited by 11
Prophylaxis for adults with haemophilia: towards a personalised approach?
Franchini, M., & Mannucci, P. M. (2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0182-11 · Cited by 11
Wada, H., Shiraki, K., Matsumoto, T., Ohishi, K., Shimpo, H., Sakano, Y., Nishii, H., & Shimaoka, M. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620976913 · Cited by 10
“Extended half-life FVIII (EHL-FVIII), which reduces the numbers of injections, would substantially improve the treatment options for hemophilia A patients.(11,12) The attachment of polyethylene glycol (PEG) has been considered an effective method for prolonging the half-life of recombinant FVIII.”
BackgroundManagement of children with hemophilia A on emicizumab who need surgery
Belletrutti, M., Bhatt, M. D., & Samji, N. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1155853 · Cited by 10
“In many areas of the world, prophylactic FVIII replacement to prevent bleeding is the standard of care, especially in children (2, 3).”
BackgroundT2 mapping magnetic resonance imaging of cartilage in hemophilia
Brakel, B. A., Sussman, M. S., Majeed, H., Teitel, J. M., Man, C., Rayner, T., Weiss, R., Moineddin, R., Blanchette, V. S., & Doria, A. S. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102182 · Cited by 10
“Whereas some joints with a large number of prior hemarthrosis at the time of the baseline MRI present with normal follow-up MRI scores, some joints with no clinically evident hemarthrosis at baseline may demonstrate the development of marked cartilage damage on the follow-up MRI, as previously reported [9].”
BackgroundMethodInfluentialTyrrell, P. N., Román, M. T. Á., Bakeer, N., Brand‐Staufer, B., Jiménez‐Yuste, V., Kras, S., Martinoli, C., Mendez, M., Nagao, A., Ozelo, M. C., et al. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102602 · Cited by 13
Spotlight on the human factor: building a foundation for the future of haemophilia A management
Kessler, C. M., Oldenburg, J., Ettingshausen, C. E., Tiede, A., Khair, K., Négrier, C., & Klamroth, R. (2014) · Haemophilia · doi:10.1111/hae.12582 · Cited by 10
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.
Calizzani, G., Profili, S., Candura, F., Lanzoni, M., Vaglio, S., Cannata, L., Liumbruno, G. M., Franchini, M., Mannucci, P. M., & Grazzini, G. (2013) · Europe PMC (PubMed Central) · doi:10.2450/2013.011s · Cited by 11
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients
Teitel, J. M., Berntorp, E. E., Dolan, G., Fischer, K., Gringeri, A., Kessler, C. M., LAMBERT, T., Leissinger, C., Nemes, L., & Shima, M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02440.x · Cited by 10
Self-citationAcharya, S. S., & Sarangi, S. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801368-7.00015-6 · Cited by 10
How do we optimally utilize factor concentrates in persons with hemophilia?
Lim, M. Y. (2021) · Hematology · doi:10.1182/hematology.2021000310 · Cited by 11
Sharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub4 · Cited by 10
The Effect of PEGylation on Drugs’ Pharmacokinetic Parameters; from Absorption to Excretion
Khajeei, A., Masoomzadeh, S., Gholikhani, T., & Javadzadeh, Y. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230621124953 · Cited by 11
Konkle, B. A., Oldenburg, J., Pasi, J., Kulkarni, R., Nolan, B., Mahlangu, J. N., Young, G. A., Brown, S. A., Pabinger, I., Shapiro, A. D., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102180 · Cited by 10
“The Joint Outcome Study and Joint Outcome Continuation study found that even low joint ABRs which are not clinically evident can lead to joint damage [4,30], highlighting the importance of preventing joint bleeds and starting prophylaxis before their occurrence.”
BackgroundSelf-citationExtravascular factor IX pool fed by prophylaxis is a true hemostatic barrier against bleeding
Leuci, A., Enjolras, N., Marano, M., Daniel, M., Brevet, M., Connes, P., & Dargaud, Y. G. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.11.023 · Cited by 10
Use of emergency medical identification in the paediatric haemophilia population: a national study
Gorlin, J. B., Hooke, M. C., & Leonard, N. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02415.x · Cited by 10
McCarthy, A., Moore, A. P., Redhead, L., McLaughlin, P., Iorio, A., & Chowdary, P. (2014) · Haemophilia · doi:10.1111/hae.12500 · Cited by 12
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.